169 related articles for article (PubMed ID: 24433088)
21. Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease.
Pianko MJ; Terpos E; Roodman GD; Divgi CR; Zweegman S; Hillengass J; Lentzsch S
Clin Cancer Res; 2014 Dec; 20(23):5888-97. PubMed ID: 25294899
[TBL] [Abstract][Full Text] [Related]
22. Transcriptomic profile induced in bone marrow mesenchymal stromal cells after interaction with multiple myeloma cells: implications in myeloma progression and myeloma bone disease.
Garcia-Gomez A; De Las Rivas J; Ocio EM; Díaz-Rodríguez E; Montero JC; Martín M; Blanco JF; Sanchez-Guijo FM; Pandiella A; San Miguel JF; Garayoa M
Oncotarget; 2014 Sep; 5(18):8284-305. PubMed ID: 25268740
[TBL] [Abstract][Full Text] [Related]
23. Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.
Bianchi G; Anderson KC
CA Cancer J Clin; 2014; 64(6):422-44. PubMed ID: 25266555
[TBL] [Abstract][Full Text] [Related]
24. Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction.
Cicci JD; Buie L; Bates J; van Deventer H
Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):e207-11. PubMed ID: 25128013
[No Abstract] [Full Text] [Related]
25. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy.
Patel CG; Yee AJ; Scullen TA; Nemani N; Santo L; Richardson PG; Laubach JP; Ghobrial IM; Schlossman RL; Munshi NC; Anderson KC; Raje NS
Clin Cancer Res; 2014 Aug; 20(15):3955-61. PubMed ID: 24958808
[TBL] [Abstract][Full Text] [Related]
26. Advances in supportive care for multiple myeloma.
Raje NS; Yee AJ; Roodman GD
J Natl Compr Canc Netw; 2014 Apr; 12(4):502-11. PubMed ID: 24717569
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Terpos E; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA
Blood Cancer J; 2018 Jan; 8(1):7. PubMed ID: 29330358
[TBL] [Abstract][Full Text] [Related]
28. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
Rajkumar SV; Dimopoulos MA; Palumbo A; Blade J; Merlini G; Mateos MV; Kumar S; Hillengass J; Kastritis E; Richardson P; Landgren O; Paiva B; Dispenzieri A; Weiss B; LeLeu X; Zweegman S; Lonial S; Rosinol L; Zamagni E; Jagannath S; Sezer O; Kristinsson SY; Caers J; Usmani SZ; Lahuerta JJ; Johnsen HE; Beksac M; Cavo M; Goldschmidt H; Terpos E; Kyle RA; Anderson KC; Durie BG; Miguel JF
Lancet Oncol; 2014 Nov; 15(12):e538-48. PubMed ID: 25439696
[TBL] [Abstract][Full Text] [Related]
29. Development of a whole spinal MRI-based tumor burden scoring method in participants with multiple myeloma: a pilot study of prognostic significance.
Cui S; Guo Y; Li J; Bian W; Wu W; Zhang W; Zheng Q; Guan H; Wang J; Niu J
Ann Hematol; 2024 May; 103(5):1665-1673. PubMed ID: 38326481
[TBL] [Abstract][Full Text] [Related]
30. New diagnostic strategy for multiple myeloma: A review.
Xu L; Wu S
Medicine (Baltimore); 2023 Dec; 102(52):e36660. PubMed ID: 38206744
[TBL] [Abstract][Full Text] [Related]
31. Osteocytes: New Kids on the Block for Cancer in Bone Therapy.
Anloague A; Delgado-Calle J
Cancers (Basel); 2023 May; 15(9):. PubMed ID: 37174109
[TBL] [Abstract][Full Text] [Related]
32. Normalization of the Immunological Microenvironment and Sustained Minimal Residual Disease Negativity: Do We Need Both for Long-Term Control of Multiple Myeloma?
Bertuglia G; Cani L; Larocca A; Gay F; D'Agostino M
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555520
[TBL] [Abstract][Full Text] [Related]
33. Progress of modern imaging modalities in multiple myeloma.
Terao T; Matsue K
Int J Hematol; 2022 Jun; 115(6):778-789. PubMed ID: 35532876
[TBL] [Abstract][Full Text] [Related]
34. GFI1-Dependent Repression of
Petrusca DN; Mulcrone PL; Macar DA; Bishop RT; Berdyshev E; Suvannasankha A; Anderson JL; Sun Q; Auron PE; Galson DL; Roodman GD
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159039
[TBL] [Abstract][Full Text] [Related]
35. Mechanical unloading aggravates bone destruction and tumor expansion in myeloma.
Tanimoto K; Hiasa M; Tenshin H; Teramachi J; Oda A; Harada T; Higa Y; Sogabe K; Oura M; Sumitani R; Hara T; Endo I; Matsumoto T; Tanaka E; Abe M
Haematologica; 2022 Mar; 107(3):744-749. PubMed ID: 34788982
[No Abstract] [Full Text] [Related]
36. Four and a Half LIM Domains Protein 2 Mediates Bortezomib-Induced Osteogenic Differentiation of Mesenchymal Stem Cells in Multiple Myeloma Through p53 Signaling and β-Catenin Nuclear Enrichment.
Xie Z; Xu Y; Wei X; An G; Hao M; Yu Z; Qiu L
Front Oncol; 2021; 11():729799. PubMed ID: 34589431
[TBL] [Abstract][Full Text] [Related]
37. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity.
Sabol HM; Ferrari AJ; Adhikari M; Amorim T; McAndrews K; Anderson J; Vigolo M; Lehal R; Cregor M; Khan S; Cuevas PL; Helms JA; Kurihara N; Srinivasan V; Ebetino FH; Boeckman RK; Roodman GD; Bellido T; Delgado-Calle J
Cancer Res; 2021 Oct; 81(19):5102-5114. PubMed ID: 34348968
[TBL] [Abstract][Full Text] [Related]
38. Role of Osteocytes in Cancer Progression in the Bone and the Associated Skeletal Disease.
Adhikari M; Delgado-Calle J
Curr Osteoporos Rep; 2021 Jun; 19(3):247-255. PubMed ID: 33818732
[TBL] [Abstract][Full Text] [Related]
39. Management of Myeloma Bone Lesions.
Du JS; Yen CH; Hsu CM; Hsiao HH
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806209
[TBL] [Abstract][Full Text] [Related]
40. Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background.
Papanota AM; Karousi P; Kontos CK; Ntanasis-Stathopoulos I; Scorilas A; Terpos E
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33673480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
